Home
University & Research Institutions

Sector: University & Research Institutions

How a DNA sequencing start-up proved it is no pushover

TwinStrand co-founder’s grandfather famously didn’t patent the polio vaccine, but Dr Jesse Salk believes that protecting inventions is key to getting products to reach the market

Historic CRISPR drug approval heralds new era in Cas9 IP wars

Green light for first ever Cas9 therapy ushers in next phase of licensing and litigation efforts.

CRISPR-Cas9 drugmakers like Vertex should come to the table early, says ToolGen’s IP chief

Chief Legal Officer Yoori Kim argues that current patent uncertainty should fuel rather than thwart licensing deals

Latest content

European plausibility uncertainties could be cleared up by new Enlarged Board of Appeal referral

The EPO is seeking clarity on a crucial question facing patentees, but not everyone is sure that a recent referral is the best vehicle

04 November 2021

What patent numbers say about the quantum technology race

The Long Read: A gap between scientific publications and patent filings in quantum fields paints a worrying picture for European innovators, in particular, write Sebastien Ragot and Michel Kurek. However, there is still time for course correction

03 November 2021

Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool

The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine

02 November 2021

Flexibility crucial to growing appeal of big money drug royalty transactions, says leading deal-maker

In the wake of the firm’s latest $250 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband gives the inside track on life sciences IP-backed revenue sales

01 November 2021

Covid-19 patent disputes highlight safe harbour uncertainties for research tool innovators

Allele Therapeutics’ suits against Pfizer and Regeneron could have big implications for the extent to which platforms can monetise IP

26 October 2021

Hub and spoke IP strategies are generating billions of dollars in biopharma

New Crinetics spin-off is more evidence of the growing influence of models designed to monetise non-core life sciences assets

22 October 2021

EU-wide SPCs would make unitary patent system more attractive, says Bayer IP chief

Joerg Thomaier believes unitary supplementary protection certificates should be introduced to coincide with the roll-out of the UPC

21 October 2021

Ranking as Asia’s most innovative economy highlights South Korea’s need for IP value creation

World-beating R&D and patent rates propel country to top of Asia for the first time in annual WIPO study, but Global Innovation Index also shows areas where IP professionals can help it improve further

27 September 2021

NPE litigation in the US bounces back

The Long Read: Sector-by-sector analysis reveals that transport, financial services and networking all recorded triple-digit percentage growth in patent suits filed by non-practising entities between 2018 and 2020, writes IAM data reporter Bridget Diakun

22 September 2021

CAFC overturns $1.2 billion damages in another Section 112 blow for biotech genus IP

Juno Therapeutics and its partner Sloan Kettering Memorial Cancer Center lose out after the Federal Circuit invalidates a key patent under written description rules

02 September 2021

Unlock unlimited access to all IAM content